Ovarian cancer is one of the common gynecological reproductive system tumors, the incidence rate is second only to cervical cancer and endometrial cancer, but the mortality rate is the first in gynecological tumors. The treatment of ovarian cancer has always been the most difficult challenge for gynecologic cancer, because the clinical symptoms of early ovarian cancer are not obvious, and it is advanced in the diagnosis.Ideal cytoreductive surgery is the cornerstone of ovarian cancer treatment. Platinum-based combination therapy is the main treatment for ovarian cancer chemotherapy. Even if patients with advanced disease receive initial relief after the above standard treatment, 70%-80% of patients will appear. Recurrence and subsequent development of resistance to standard therapies. In recent years, many studies have suggested that the research advantages of cytokines in the field of ovarian cancer are gradually highlighted. In ovarian cancer, cytokines regulate the proliferation, survival, angiogenesis, and metastasis of tumor cells. They produce an autocrine effect on the tumor microenvironment, triggering tumor cells to activate immune regulation mechanisms to evade immune surveillance. Interleukin-6 (IL-6) is a pro-inflammatory cytokine, a core player in chronic inflammatory diseases including cancer, and a major immunoregulatory cytokine in the tumor microenvironment. Previous studies have shown that overexpression of IL-6 in ovarian cancer tissues activates related pathways such as JAK/STAT, Ras/ERK/MAPK, and PI3 K/AKT to promote tumor cell proliferation, anti-apoptosis, induction of vascular proliferation, cell infiltration and drug resistance. IL-6 is a key cytokine and an independent predictor for the development and progression of ovarian cancer. It is expected to provide new ideas for the early diagnosis and treatment of ovarian cancer. This article reviews the progress of IL-6 in ovarian cancer.
DownLoad: